Acarix AB (publ) (ACARIX.ST)
SEK 0.25
(-4.05%)
SEK 0.25
(-4.05%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -77.55 Million SEK | -1.41% |
| 2022 | -76.47 Million SEK | -47.93% |
| 2021 | -51.69 Million SEK | -24.78% |
| 2020 | -41.43 Million SEK | 10.79% |
| 2019 | -46.44 Million SEK | -9.22% |
| 2018 | -42.52 Million SEK | -38.32% |
| 2017 | -30.74 Million SEK | -14.76% |
| 2016 | -26.79 Million SEK | -74.22% |
| 2015 | -15.37 Million SEK | 35.9% |
| 2014 | -23.98 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -14.92 Million SEK | 32.15% |
| 2024 Q2 | -16.57 Million SEK | -11.07% |
| 2023 Q4 | -21.99 Million SEK | -27.71% |
| 2023 FY | -77.55 Million SEK | -1.41% |
| 2023 Q2 | -21.89 Million SEK | -33.24% |
| 2023 Q3 | -17.22 Million SEK | 21.33% |
| 2023 Q1 | -16.43 Million SEK | 27.33% |
| 2022 Q2 | -18.38 Million SEK | -24.63% |
| 2022 FY | -76.47 Million SEK | -47.93% |
| 2022 Q1 | -14.74 Million SEK | 9.06% |
| 2022 Q4 | -22.61 Million SEK | -9.08% |
| 2022 Q3 | -20.73 Million SEK | -12.79% |
| 2021 FY | -51.69 Million SEK | -24.78% |
| 2021 Q2 | -13.09 Million SEK | -12.06% |
| 2021 Q3 | -10.7 Million SEK | 18.26% |
| 2021 Q4 | -16.21 Million SEK | -51.53% |
| 2021 Q1 | -11.68 Million SEK | -2.61% |
| 2020 Q3 | -8.88 Million SEK | 14.21% |
| 2020 FY | -41.43 Million SEK | 10.79% |
| 2020 Q4 | -11.38 Million SEK | -28.12% |
| 2020 Q2 | -10.36 Million SEK | 4.03% |
| 2020 Q1 | -10.79 Million SEK | -8.12% |
| 2019 Q3 | -11.32 Million SEK | 7.94% |
| 2019 Q4 | -9.98 Million SEK | 11.86% |
| 2019 FY | -46.44 Million SEK | -9.22% |
| 2019 Q1 | -12.82 Million SEK | -5.21% |
| 2019 Q2 | -12.3 Million SEK | 4.09% |
| 2018 Q1 | -8.01 Million SEK | 34.55% |
| 2018 FY | -42.52 Million SEK | -38.32% |
| 2018 Q4 | -12.19 Million SEK | 4.51% |
| 2018 Q3 | -12.77 Million SEK | -33.75% |
| 2018 Q2 | -9.54 Million SEK | -19.19% |
| 2017 Q1 | -3.93 Million SEK | 73.85% |
| 2017 Q2 | -6.99 Million SEK | -77.83% |
| 2017 Q3 | -7.57 Million SEK | -8.34% |
| 2017 FY | -30.74 Million SEK | -14.76% |
| 2017 Q4 | -12.23 Million SEK | -61.53% |
| 2016 Q3 | -6.99 Million SEK | -184.54% |
| 2016 Q1 | -2.29 Million SEK | -1.68% |
| 2016 FY | -26.79 Million SEK | -74.22% |
| 2016 Q4 | -15.04 Million SEK | -115.08% |
| 2016 Q2 | -2.45 Million SEK | -7.15% |
| 2015 Q4 | -2.25 Million SEK | 0.0% |
| 2015 FY | -15.37 Million SEK | 35.9% |
| 2014 FY | -23.98 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ADDvise Group AB (publ) | 300.6 Million SEK | 125.799% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 125.799% |
| Arcoma AB | 4.66 Million SEK | 1764.227% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 41.218% |
| BICO Group AB (publ) | -618.3 Million SEK | 87.457% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 297.487% |
| CellaVision AB (publ) | 167.05 Million SEK | 146.425% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | -17.624% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | -162.255% |
| C-Rad AB (publ) | 44.24 Million SEK | 275.285% |
| Duearity AB (publ) | -25.76 Million SEK | -201.025% |
| Dignitana AB (publ) | -15.02 Million SEK | -416.125% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 18.193% |
| Getinge AB (publ) | 3.81 Billion SEK | 102.033% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | -13.306% |
| Iconovo AB (publ) | -45.77 Million SEK | -69.416% |
| Integrum AB (publ) | 6.51 Million SEK | 1290.862% |
| Luxbright AB (publ) | -25.8 Million SEK | -200.541% |
| Mentice AB (publ) | -679 Thousand SEK | -11321.649% |
| OssDsign AB (publ) | -91.95 Million SEK | 15.663% |
| Paxman AB (publ) | 12.61 Million SEK | 714.573% |
| Promimic AB (publ) | -9.11 Million SEK | -750.548% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 54.028% |
| SciBase Holding AB (publ) | -53.93 Million SEK | -43.779% |
| ScandiDos AB (publ) | -13.48 Million SEK | -475.191% |
| Sectra AB (publ) | 518.49 Million SEK | 114.957% |
| Sedana Medical AB (publ) | -65.54 Million SEK | -18.317% |
| Senzime AB (publ) | -133.74 Million SEK | 42.014% |
| SpectraCure AB (publ) | -21.35 Million SEK | -263.229% |
| Stille AB | 44.95 Million SEK | 272.524% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 97.839% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 301.405% |